*aureus* strains with reduced susceptibility to vancomycin[31-33]). To avoid the rapid emergence of such strains, it is recommended that hospitals implement an antimicrobial audit and use program to prevent prolonged and sometimes unnecessary course of vancomycin therapy; enhance infection control programs to control multidrug-resistant organisms; and ensure that laboratories are testing staphylococci for vancomycin resistance, preferably by MIC methods, especially for isolates from sterile sites.

## REFERENCES


1. Shulman JA, Nahmias AJ. Staphylococcal infection: clinical aspects. In: Cohen JO, ed. *The Staphylococci.* New York, NY: Wiley-Interscience; 1972:457-502.
2. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. *Am J Med* 1991;91(3B):86S-89S.
3. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. *Am J Med* 1991;91(3B):72S-75S.
4. Emory TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev* 1993;6: 428-442.
5. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. *Ann Intern Med* 1989;110:9-16.
6. Karchmer AW, Archer GL, Dismukes WE. *Staphylococcus epidermidis* causing prosthetic valve endocarditis: microbiologic and clinical observations as guide to therapy. *Ann Intern Med* 1983;98:447-455.
7. Archer GL, Tenenbaum MJ. Antibiotic resistant *Staphylococcus epidermidis* in patients undergoing cardiac surgery. *Antimicrob Agents Chemother* 1980;17:269-272.
8. Griffith RS. Vancomycin use-an historical review. *J Antimicrob Chemother* 1988;32:24-26.
9. Watanakunakorn C. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. *J Antimicrob Chemother* 1988;22:321-324.
10. Hancock R, Fitz-James PC. Some differences in the action of penicillin, bacitracin, and vancomycin on *Bacillus megaterium. J Bacteriol* 1964;87:1044-1050.
11. Jordan DC, Inniss WE. Selective inhibition of ribonucleic acid synthesis in *Staphylococcus aureus* by vancomycin. *Nature* 1959;184:1894-1895.
12. Goldstein FW, Coutrot A, Sieffer A, Acar JF. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. *Antimicrob Agents Chemother* 1990;34:899-900.
13. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP. Vancomycin resistance in *Staphylococcus haemolyticus* causing colonization and bloodstream infection. *J Clin Microbiol* 1990;28:2064-2068.
14. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. *N Engl J Med* 1987;316:927-931.
15. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH. Selection for vancomycin resistance in clinical isolates of *Staphylococcus haemolyticus. J Infect Dis* 1990;161:45-51.
16. Tuazon CU, Miller H. Clinical and microbiologic aspects of serious infections caused by *Staphylococcus epidermidis. Scand J Infect Dis* 1983;15:347-360.
17. Cherubin CE, Corrado ML, Sierra MF, Gombert ME, Shulman M. Susceptibility of gram-positive cocci to various antibiotics including cefotaxime, moxalactam, and N-formimidoyl thienamycin. *Antimicrob Agents Chemother* 1981;20:553-555.
18. Sanyal D, Johnson AP, George RC, Cookson BD, Williams AJ. Peritonitis due to vancomycin-resistant *Staphylococcus epidermidis. Lancet* 1991;337:54.
19. Krcmery V, Trupl J, Drgona L, Lacka J, Kukuckova E, Oravcova E. Nosocomial bacteremia due to vancomycin-resistant *Staphylococcus epidermidis* in four patients with cancer, neutropenia, and previous treatment with vancomycin. *Eur J Clin Microbiol Infect Dis* 1996;15:259-261.
20. Kloos WE, Bannerman TL. *Staphylococcus* and *Micrococcus.* In: *Manual of Clinical Microbiology,* 6th ed. Washington, DC: American Society for Microbiology; 1995:282-298.
21. National Committee for Clinical Laboratory Standards. Second Performance Standards for Antimicrobic Disk Susceptibility Tests. Approved standard MZ-A25. Villanova, PA: NCCLS; 1982.
22. Washington JA II, Sutter VL. Dilution susceptibility test: agar and macrobroth dilution procedures. In: Lennette EA, Ballows A, Hausler WJ Jr, Truant JP, eds. *Manual of Clinical Microbiology.* 3rd ed. Washington, DC: American Society for Microbiology; 1980:453-458.
23. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 4th ed. Approved standard M7-A4. Wayne, PA: NCCLS; 1997.
24. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. 6th ed. Approved standard M2-A6. Wayne, PA: NCCLS; 1997.
25. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from US hospitals. *Antimicrob Agents Chemother* 1993;37:2311-2317.
26. Satake S, Clark N, Rimland D, Nolte FS, Tenover FC. Detection of vancomycin-resistant enterococci in fecal samples by using the polymerase chain reaction. *J Clin Microbiol* 1997;35:2325-2330.
27. Bannerman TL, Hancock GA, Tenover FC, Miller JM. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of *Staphylococcus aureus. J Clin Microbiol* 1995;33:551-555.
28. Sattler FR, Foderano JB, Aber RC. *Staphylococcus epidermidis* bacteremia associated with vascular catheters: an important cause of febrile morbidity in hospitalized patients. *Infect Control* 1984;5:279-283.
29. Smith DJ, Kaplan RL, Landau W, Trenholme GM. Speciation and antibiotic susceptibility patterns of coagulase-negative staphylococci. *Eur J Clin Microbiol* 1982;1:228-232.
30. Swenson JM, Hill BC, Thornsberry C. Problems with the disk diffusion test for detection of vancomycin resistance in enterococci. *J Clin Microbiol* 1989;27:2140-2142.
31. Centers for Disease Control and Prevention. *Staphylococcus aureus* with reduced susceptibility to vancomycin-United States, 1997. *MMWR* 1997;46:756-766.
32. Centers for Disease Control and Prevention. Update: *Staphylococcus aureus* with reduced susceptibility to vancomycin-United States, 1997. *MMWR* 1997;46:813-815.
33. Smith TL, Pearson M, Tenover F, Jarvis WR. Emergence of vancomycin resistance in *Staphylococcus aureus:* epidemiology and clinical significance. *N Engl J Med.* In press.


# Continuing Education Credits Offered for CDC Reports

**Gina Pugliese, RN, MS**
**Martin S. Favero, PhD**

The CDC is offering continuing medical education (CME) and continuing nursing education (CNE) credits for selected reports and recommendations published in the *Morbidity and Mortality Weekly Report.* To register and to receive credit, physicians and nurses must return their responses either electronically to the World Wide Web site (http://www.cdc.gov/epo/mmwr/mmwr.html, then go to Continuing Education Program for Physicians and Nurses) or by mail. There is no fee for participating in this continuing education activity. CME and CNE components are planned for future *MMWR* Recommendations and Reports.

FROM: Centers for Disease Control and Prevention. Notice to readers: availability of continuing medical education component in the *MMWR* Recommen-dations and Reports series. *MMWR* 1998;47:912.

https://doi.org/10.1017/S0195941700068077 Published online by Cambridge University Press